IN THE CLAIMS

Please amend the claims as follows:

- 1-131. (Cancelled).
- 132. (Previously Presented) A compound that is a substrate of a cytochrome P450 enzyme and a pro-substrate of a luciferase enzyme, wherein the compound is a structural analog of luciferin, dehydroluciferin or luciferol that includes a substitution at the 6' hydroxy site of luciferin or luciferol or the corresponding 6' site of dehydroluciferin, which substitution includes

 C_{1-20} alkoxy or C_{1-20} alkenyloxy wherein the alkoxy and alkenyloxy are substituted with halogen, hydroxy, amino, cyano, azido, heteroaryl or aryl substituted with haloalkyl; or

 $C_{3\cdot20}$ alkynyloxy; cycloalkoxy, cycloalkylamino, $C_{1\cdot20}$ alkylamino, di $C_{1\cdot20}$ alkynlamino, $C_{2\cdot20}$ alkenylamino, di $C_{2\cdot20}$ alkenylamino, $C_{2\cdot20}$ alkenylamino, $C_{3\cdot20}$ alkynylamino, di $C_{3\cdot20}$ alkynylamino, $C_{3\cdot20}$ alkynylamino, or $C_{3\cdot20}$ alkynylamin

- (Currently Amended) A composition comprising a compound of claim 132 and a buffer.
 - 134. (Original) The composition of claim 133, further comprising a pyrophosphatase.
 - 135. (Cancelled).
 - 136. (Cancelled).
 - 137. (Original) A compound selected from the group consisting of luciferin 6' 2-chloroethyl ether;

luciferin 6' benzyl ether

luciferin 6' 4-picolinyl ether;

Filing Date: September 19, 2003

Title: LUMINESCENCE-BASED METHODS AND PROBES FOR CYTOCHROME P450 ACTIVITY

luciferin 6' 4-trifluoromethylbenzyl ether;

luciferin 6' phenylethyl ether

luciferin 6' geranyl ether

luciferin 6' prenyl ether

luciferin 6' 2-picolinyl ether; and

luciferin 6' 3-picolinyl ether.

(Original) The compound according to claim 137 selected from the group consisting of

luciferin 6' benzyl ether;

luciferin 6' phenylethyl ether;

luciferin 6' geranyl ether; and

luciferin 6' prenyl ether.

(Previously Presented) The compound according to claim 137 selected from the group consisting of

luciferin 6' 2-chloroethyl ether;

luciferin 6' 4-picolinyl ether;

luciferin 6' 4-trifluoromethylbenzyl ether;

luciferin 6' 2-picolinyl ether; and

luciferin 6' 3-picolinyl ether.

140-167. (Cancelled).

(Previously Presented) The composition according to claim 134 wherein the pyrophosphatase is an inorganic pyrophosphatase.

169. (Previously Presented) A compound having the formula:

$$R_1$$
 R_2 R_4 R_6 R_6

wherein

- R_1 represents hydrogen, hydroxy, C_{1-20} alkoxy or C_{1-20} alkenyloxy, wherein the alkoxy and alkenyloxy are substituted with halogen, hydroxy, amino, cyano, azido, heteroaryl or aryl substituted with halogleyl; or
- $$\begin{split} R_1 \text{ represents } C_{3:20} \text{ alkynyloxy; cycloalkoxy, cycloalkylamino, } C_{1:20} \text{ alkylamino, } \text{diC}_{1:20} \\ \text{ alkylamino, } C_{2:20} \text{ alkenylamino, } \text{diC}_{2:20} \text{ alkenylamino, } C_{2:20} \text{ alkenyl } C_{1:20} \text{ alkynylamino, } \text{or } C_{3:20} \text{ alkynylamino, } \text{or } C_{3$$

 R_2 and R_3 independently represent C or N;

- R_4 and R_5 independently represent S, O, NR₈ wherein R_8 represents hydrogen or $C_{1\cdot 20}$ alkyl, or CR_9R_{10} wherein R_9 and R_{10} independently represent H, $C_{1\cdot 20}$ alkyl or fluorine;
- R₆ represents CH₂OH; COR₁₁ wherein R₁₁ represents hydrogen, hydroxy, C₂₋₂₀ alkenyl, or -OM⁺ wherein M⁺ is an alkali metal or a pharmaceutically acceptable salt; and
- R_7 represents hydrogen, $C_{1\text{--}6}$ alkyl, $C_{2\text{--}20}$ alkenyl, halogen or $C_{1\text{--}6}$ alkoxy; provided that
- when R_1 is hydroxy, R_7 is not hydrogen, R_{11} is not hydroxy, R_2 and R_3 are not both carbon, and R_4 and R_5 are not both S (luciferin);
- when R_1 is hydrogen, R_7 is not hydrogen, R_{11} is not hydroxy, R_2 and R_3 are not both carbon, and R_4 and R_5 are not both S (dehydroluciferin); and
- when R₁ is hydroxy, R₇ is not hydrogen, R₆ is not CH₂OH, R₂ and R₃ are not both carbon, and R₄ and R₅ are not both S (luciferol).
- (Currently Amended) A composition comprising a compound of claim 169 and a buffer.

- 171. (Previously Presented) The composition of claim 170, further comprising a pyrophosphatase.
- 172. (Previously Presented) The composition according to claim 171 wherein the pyrophosphatase is an inorganic pyrophosphatase.
- 173. (Previously Presented) The compound according to claim 169 selected from the group consisting of

luciferin 6' 2-chloroethyl ether;

luciferin 6' 4-picolinyl ether:

luciferin 6' 4-trifluoromethylbenzyl ether;

luciferin 6' 2-picolinyl ether; or

luciferin 6' 3-picolinyl ether.

- 174. (Currently Amended) A composition comprising a compound of claim 173 and a buffer.
- 175. (Previously Presented) The composition of claim 174, further comprising a pyrophosphatase.
- 176. (Previously Presented) The composition according to claim 175 wherein the pyrophosphatase is an inorganic pyrophosphatase.
- 177. (Previously Presented) The compound according to claim 169 selected from the group consisting of

luciferin 6' benzyl ether;

luciferin 6' phenylethyl ether;

luciferin 6' geranyl ether; and

luciferin 6' prenyl ether.

- 178. (Currently Amended) A composition comprising a compound of claim 177 and a buffer.
- (Previously Presented) The composition of claim 178, further comprising a pyrophosphatase.
- 180. (Previously Presented) The composition according to claim 179 wherein the pyrophosphatase is an inorganic pyrophosphatase.
- 181. (Previously Presented) The compound according to claim 169 that has the structure

or a salt thereof.

182. (Previously Presented) The compound according to claim 169 that has the structure

or a salt thereof.

183. (Previously Presented) The compound according to claim 169 that has the structure

$$\text{N} \text{S}^{\text{CO}_2\text{H}}$$

or a salt thereof.

184. (Previously Presented) The compound according to claim 169 that has the structure

or a salt thereof.

185. (Previously Presented) The compound according to claim 169 that has the structure

or a salt thereof.

186. (Previously Presented) The compound according to claim 169 that has the structure

or a salt thereof.

187. (Previously Presented) The compound according to claim 169 that has the structure

or a salt thereof.

 (Previously Presented) The compound according to claim 169 that has the structure

$$\text{S}^{\text{CO}_2 \text{H}}$$

or a salt thereof.

189. (Previously Presented) The compound according to claim 169 that has the structure

or a salt thereof

- 190. (Withdrawn; Previously Presented) A kit for determining the effect of a substance on cytochrome P450 enzyme activity comprising:
- (a) one or more luminogenic compounds wherein the compound is a cytochrome P450 enzyme substrate and a pro-substrate of luciferase enzyme, wherein the compound is a structural analog of luciferin, dehydroluciferin or luciferol that includes a substitution at the 6' hydroxy site of luciferin or luciferol or the corresponding 6' site of dehydroluciferin, which substitution includes

 C_{1-20} alkoxy or C_{1-20} alkenyloxy wherein the alkoxy and alkenyloxy are substituted with halogen, hydroxy, amino, cyano, azido, heteroaryl or aryl substituted with haloalkyl; or

 $C_{3\cdot20}$ alkynyloxy; cycloalkoxy, cycloalkylamino, $C_{1\cdot20}$ alkylamino, di $C_{1\cdot20}$ alkynylamino, $C_{2\cdot20}$ alkenylamino, di $C_{2\cdot20}$ alkenylamino, $C_{2\cdot20}$ alkenylamino, $C_{3\cdot20}$ alkynylamino, $C_{3\cdot20}$ alkynylamino, $C_{3\cdot20}$ alkynylamino, or $C_{3\cdot20}$ alkynylamino, $C_{3\cdot20}$ alkynylamino, or $C_{3\cdot20}$ alkynylamino, or $C_{3\cdot20}$ alkynylamino, or $C_{3\cdot20}$ alkynylamino, or $C_{3\cdot20}$ alkynylamino, or one or $C_{3\cdot20}$ alkynylamino, o

- (b) directions for using the kit.
- 191. (Withdrawn; Previously Presented) The kit according to claim 190, further comprising one or more bioluminescent enzymes.

- 192. (Withdrawn; Previously Presented) The kit according to claim 191 wherein the bioluminescent enzyme is a luciferase.
- 193. (Withdrawn; Previously Presented) The kit according to claim 191 wherein the bioluminescent enzyme is a firefly or a Renilla luciferase.
- 194. (Withdrawn; Previously Presented) The kit according to claim 190 further comprising ATP and magnesium ions.
- 195. (Withdrawn; Previously Presented) The kit according to claim 194 further comprising a detergent.
- 196. (Withdrawn; Previously Presented) The kit according to claim 195 wherein the detergent is non-ionic.
- 197. (Withdrawn; Previously Presented) The kit according to claim 195 further comprising a pyrophosphatase.
- 198. (Withdrawn; Previously Presented) The kit according to claim 197 wherein the pyrophosphatase is an inorganic pyrophosphatase.
- 199. (Withdrawn; Previously Presented) The kit according to claim 198 wherein the compound has the formula:

$$R_{3}$$
 R_{4}
 R_{5}
 R_{6}
 R_{6}

wherein

Page 10 Dkt: 341.044US1

- R₁ represents hydrogen, hydroxy, C₁₋₂₀ alkoxy or C₁₋₂₀ alkenyloxy, wherein the alkoxy and alkenyloxy are substituted with halogen, hydroxy, amino, cyano, azido, heteroaryl or aryl substituted with haloalkyl; or
- R₁ represents C₃₋₂₀ alkynyloxy; cycloalkoxy, cycloalkylamino, C₁₋₂₀ alkylamino, diC₁₋₂₀ alkylamino, diC₁₋₂₀ alkenylamino, diC₂₋₂₀ alkenylamino, C₂₋₂₀ alkenyl C₁₋₂₀alkylamino, C₃₋₂₀ alkynylamino, diC₃₋₂₀ alkynylamino, C₃₋₂₀ alkynylamino, or C₃₋₂₀ alkynylamino, or C₃₋₂₀ alkynylamino, cycloalkylamino, or C₃₋₂₀ alkynylamino, or C₃₋₂₀ alkynylam
- R2 and R3 independently represent C or N;
- R_4 and R_5 independently represent S, O, NR₈ wherein R_8 represents hydrogen or C_{1-20} alkyl, or CR_9R_{10} wherein R_9 and R_{10} independently represent H, C_{1-20} alkyl or fluorine;
- R₆ represents CH₂OH; COR₁₁ wherein R₁₁ represents hydrogen, hydroxy, C₂₋₂₀ alkenyl, or -OM⁺ wherein M⁺ is an alkali metal or a pharmaceutically acceptable salt; and
- R₇ represents hydrogen, C₁₋₆ alkyl, C₂₋₂₀ alkenyl, halogen or C₁₋₆ alkoxy; provided that when R₁ is hydroxy, R₇ is not hydrogen, R₁₁ is not hydroxy, R₂ and R₃ are not both carbon, and R₄ and R₅ are not both S (luciferin);
- when R_1 is hydrogen, R_7 is not hydrogen, R_{11} is not hydroxy, R_2 and R_3 are not both carbon, and R_4 and R_5 are not both S (dehydroluciferin); and
- when R₁ is hydroxy, R₂ is not hydrogen, R₆ is not CH₂OH, R₂ and R₃ are not both carbon, and R₄ and R₅ are not both S (luciferol).
- 200. (Withdrawn; Previously Presented) The kit according to claim 190, further comprising a reversible luciferase inhibitor.
- (Withdrawn; Previously Presented) The kit according to claim 200, wherein the reversible luciferase inhibitor is 2-(4-aminopheny1)-6-methylbenzothiazole (APMBT) or 2amino-46-methylbenzothiazole (AMBT).
- 202. (Withdrawn; Previously Presented) The kit according to claim 190 wherein the compound has the structure

$$CI \underbrace{\hspace{1cm} N \hspace{1cm} N}_{N} \underbrace{\hspace{1cm} N \hspace{1cm} CO_2H}_{N}$$

or a salt thereof.

203. (Withdrawn; Previously Presented) The kit according to claim 190 wherein the compound has the structure

or a salt thereof.

204. (Withdrawn; Previously Presented) The kit according to claim 190 wherein the compound has the structure

or a salt thereof.

205. (Withdrawn; Previously Presented) The kit according to claim 190 wherein the compound has the structure

or a salt thereof.

206. (Withdrawn; Previously Presented) The kit according to claim 190 wherein the compound has the structure

or a salt thereof.

207. (Withdrawn; Previously Presented) The kit according to claim 190 wherein the compound has the structure

or a salt thereof.

208. (Withdrawn; Previously Presented) The kit according to claim 190 wherein the compound has the structure

or a salt thereof.

209. (Withdrawn; Previously Presented) The kit according to claim 190 wherein the compound has the structure

or a salt thereof.

210. (Withdrawn; Previously Presented) The kit according to claim 190 wherein the compound has the structure

or a salt thereof.

- 211. (Withdrawn; Previously Presented) A kit for determining the effect of a substance on cytochrome P450 enzyme activity comprising:
- (a) one or more luminogenic compounds, wherein the compound is a cytochrome P450 enzyme substrate and a pro-substrate of luciferase enzyme, and the compound is a selected from

$$CI \longrightarrow CO_2H$$

$$CO_2H$$

Page 14 Dkt: 341.044US1

N CO₂H

or a salt thereof:

- one or more bioluminescent enzymes: (b)
- (c) a buffer; and
- (c) directions for using the kit.
- 212. (Withdrawn; Previously Presented) The kit according to claim 211 wherein the bioluminescent enzyme is a luciferase.
- 213. (Withdrawn; Previously Presented) The kit according to claim 211 wherein the bioluminescent enzyme is a firefly or a Renilla luciferase.
- 214. (Withdrawn; Previously Presented) The kit according to claim 211 further comprising ATP and magnesium ions.
- 215. (Withdrawn: Previously Presented) The kit according to claim 214 further comprising a detergent.
- 216. (Withdrawn; Previously Presented) The kit according to claim 215 wherein the detergent is non-ionic.
- 217. (Withdrawn: Previously Presented) The kit according to claim 215 further comprising a pyrophosphatase.
- 218. (Withdrawn; Previously Presented) The kit according to claim 217 wherein the pyrophosphatase is an inorganic pyrophosphatase.

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.111

Serial Number: 10/665,314 Filing Date: September 19, 2003

Title: LUMINESCENCE-BASED METHODS AND PROBES FOR CYTOCHROME P450 ACTIVITY

Page 15 Dkt: 341.044US1

- 219. (Withdrawn; Previously Presented) The kit according to claim 211, further comprising a reversible luciferase inhibitor.
- 220. (Withdrawn; Previously Presented) The kit according to claim 219, wherein the reversible luciferase inhibitor is 2-(4-aminopheny1)-6-methylbenzothiazole (APMBT) or 2-amino-46-methylbenzothiazole (AMBT).